180 related articles for article (PubMed ID: 29218452)
1. Inhibition of the K
Barriga-Montoya C; Huanosta-Gutiérrez A; Reyes-Vaca A; Hernández-Cruz A; Picones A; Gómez-Lagunas F
Pflugers Arch; 2018 Mar; 470(3):491-503. PubMed ID: 29218452
[TBL] [Abstract][Full Text] [Related]
2. Dronedarone blockage of the tumor-related Kv10.1 channel: a comparison with amiodarone.
Meléndez TA; Huanosta-Gutiérrez A; Barriga-Montoya C; González-Andrade M; Gómez-Lagunas F
Pflugers Arch; 2020 Jan; 472(1):75-87. PubMed ID: 31897736
[TBL] [Abstract][Full Text] [Related]
3. State-independent inhibition of the oncogenic Kv10.1 channel by desethylamiodarone, a comparison with amiodarone.
Gomez-Lagunas F; Barriga-Montoya C; Pardo JP
Pflugers Arch; 2024 Mar; 476(3):323-335. PubMed ID: 38063872
[TBL] [Abstract][Full Text] [Related]
4. Gating Modulation of the Tumor-Related Kv10.1 Channel by Mibefradil.
Gómez-Lagunas F; Carrillo E; Pardo LA; Stühmer W
J Cell Physiol; 2017 Aug; 232(8):2019-2032. PubMed ID: 27255432
[TBL] [Abstract][Full Text] [Related]
5. Mibefradil inhibition of the Cole-Moore shift and K
Gómez-Lagunas F; Barriga-Montoya C
Channels (Austin); 2017 Sep; 11(5):373-376. PubMed ID: 28650687
[No Abstract] [Full Text] [Related]
6. Thallium-sensitive fluorescent assay reveals loperamide as a new inhibitor of the potassium channel Kv10.1.
Loza-Huerta A; Milo E; Picones A; Hernández-Cruz A; Luis E
Pharmacol Rep; 2021 Dec; 73(6):1744-1753. PubMed ID: 34213738
[TBL] [Abstract][Full Text] [Related]
7. Correction to: Inhibition of the K
Barriga-Montoya C; Huanosta-Gutiérrez A; Reyes-Vaca A; Hernández-Cruz A; Picones A; Gómez-Lagunas F
Pflugers Arch; 2018 Jun; 470(6):981-993. PubMed ID: 29549440
[TBL] [Abstract][Full Text] [Related]
8. Chloroquine inhibits tumor-related Kv10.1 channel and decreases migration of MDA-MB-231 breast cancer cells in vitro.
Valdés-Abadía B; Morán-Zendejas R; Rangel-Flores JM; Rodríguez-Menchaca AA
Eur J Pharmacol; 2019 Jul; 855():262-266. PubMed ID: 31082369
[TBL] [Abstract][Full Text] [Related]
9. The class III anti-arrhythmic agent, amiodarone, inhibits voltage-dependent K(+) channels in rabbit coronary arterial smooth muscle cells.
Li H; Kim HS; Kim HW; Shin SE; Jung WK; Ha KS; Han ET; Hong SH; Firth AL; Bae YM; Choi IW; Park WS
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jul; 389(7):713-21. PubMed ID: 27030392
[TBL] [Abstract][Full Text] [Related]
10. Molecular Dynamics-Derived Pharmacophore Model Explaining the Nonselective Aspect of K
Toplak Ž; Merzel F; Pardo LA; Peterlin Mašič L; Tomašič T
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445705
[TBL] [Abstract][Full Text] [Related]
11. External pH modulates EAG superfamily K+ channels through EAG-specific acidic residues in the voltage sensor.
Kazmierczak M; Zhang X; Chen B; Mulkey DK; Shi Y; Wagner PG; Pivaroff-Ward K; Sassic JK; Bayliss DA; Jegla T
J Gen Physiol; 2013 Jun; 141(6):721-35. PubMed ID: 23712551
[TBL] [Abstract][Full Text] [Related]
12. Kv10.1 potassium channel: from the brain to the tumors.
Cázares-Ordoñez V; Pardo LA
Biochem Cell Biol; 2017 Oct; 95(5):531-536. PubMed ID: 28708947
[TBL] [Abstract][Full Text] [Related]
13. The Eag domain regulates the voltage-dependent inactivation of rat Eag1 K+ channels.
Lin TF; Jow GM; Fang HY; Fu SJ; Wu HH; Chiu MM; Jeng CJ
PLoS One; 2014; 9(10):e110423. PubMed ID: 25333352
[TBL] [Abstract][Full Text] [Related]
14. Ginsenoside Rg3, a Gating Modifier of EAG Family K+ Channels.
Wu W; Gardner A; Sachse FB; Sanguinetti MC
Mol Pharmacol; 2016 Oct; 90(4):469-82. PubMed ID: 27502018
[TBL] [Abstract][Full Text] [Related]
15. Pharmacological inhibition of the hERG potassium channel is modulated by extracellular but not intracellular acidosis.
DU CY; El Harchi A; Zhang YH; Orchard CH; Hancox JC
J Cardiovasc Electrophysiol; 2011 Oct; 22(10):1163-70. PubMed ID: 21489024
[TBL] [Abstract][Full Text] [Related]
16. Procyanidin B1, a novel and specific inhibitor of Kv10.1 channel, suppresses the evolution of hepatoma.
Na W; Ma B; Shi S; Chen Y; Zhang H; Zhan Y; An H
Biochem Pharmacol; 2020 Aug; 178():114089. PubMed ID: 32533968
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of novel purpurealidin analogs and evaluation of their effect on the cancer-relevant potassium channel KV10.1.
Moreels L; Bhat C; Voráčová M; Peigneur S; Goovaerts H; Mäki-Lohiluoma E; Zahed F; Pardo LA; Yli-Kauhaluoma J; Kiuru P; Tytgat J
PLoS One; 2017; 12(12):e0188811. PubMed ID: 29220359
[TBL] [Abstract][Full Text] [Related]
18. Expanding the pharmacological profile of κ-hefutoxin 1 and analogues: A focus on the inhibitory effect on the oncogenic channel K
Moreels L; Peigneur S; Yamaguchi Y; Vriens K; Waelkens E; Zhu S; Thevissen K; Cammue BPA; Sato K; Tytgat J
Peptides; 2017 Dec; 98():43-50. PubMed ID: 27578329
[TBL] [Abstract][Full Text] [Related]
19. APETx4, a Novel Sea Anemone Toxin and a Modulator of the Cancer-Relevant Potassium Channel K
Moreels L; Peigneur S; Galan DT; De Pauw E; Béress L; Waelkens E; Pardo LA; Quinton L; Tytgat J
Mar Drugs; 2017 Sep; 15(9):. PubMed ID: 28902151
[TBL] [Abstract][Full Text] [Related]
20. Kv10.1 K(+) channel: from physiology to cancer.
Ouadid-Ahidouch H; Ahidouch A; Pardo LA
Pflugers Arch; 2016 May; 468(5):751-62. PubMed ID: 26743871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
